Semaglutide vs Tirzepatide vs Retatrutide: Research Comparison

Semaglutide vs Tirzepatide vs Retatrutide

These three peptides represent the single-, dual-, and triple-agonist ends of the incretin research spectrum. This guide compares their mechanisms and technical data for research use only (RUO) — none are drugs or supplements, and none are for human or veterinary use.

The Core Difference: Receptor Targets

The simplest way to distinguish them is by how many incretin/metabolic receptors each activates:

Compound	Receptor Targets	Class
Semaglutide	GLP-1	Single agonist
Tirzepatide	GIP + GLP-1	Dual agonist
Retatrutide	GIP + GLP-1 + Glucagon	Triple agonist

Semaglutide (GLP-1)

A long-acting GLP-1 receptor agonist studied in glucose-dependent insulin-signaling and appetite-regulation models. See the full semaglutide research guide.

Tirzepatide (GIP + GLP-1)

A single peptide that activates both the GIP and GLP-1 receptors, studied for combined incretin signaling. See the full tirzepatide research guide.

Retatrutide (GIP + GLP-1 + Glucagon)

A triple agonist adding the glucagon receptor to the dual-incretin mechanism, studied in energy-expenditure and body-weight models. See the full retatrutide research guide.

Where Amylin Compounds Fit

Amylin-pathway peptides such as cagrilintide and eloralintide act on a separate (amylin) receptor system and are often studied alongside these incretin agonists.

Buy for Research

Zama Biosciences supplies SemZama, TirZama, and RetZama, all independently HPLC/LC-MS tested.

Research Use Only. Not drugs, supplements, or medical devices; not for human or veterinary use, consumption, or diagnostic application. Not evaluated by the FDA.